Once-daily Dosing
VANRAFIA: A single dose, once a day1
 |  |
VANRAFIA is available as a 0.75-mg tablet | One dose, once a day, with no need for titration and independent titration of existing therapies |
 |  |
VANRAFIA is taken | Patients should swallow tablets whole. |
VANRAFIA is an ETᴀ receptor antagonist, not a steroid, and can be added as a foundational option on to your patient’s current maximally tolerated and stable RASi ± SGLT2i regimen
If a dose is missed
If a dose or doses are missed, advise your patient to take the prescribed dose of VANRAFIA at the next scheduled time. The dose should not be doubled to make up for a missed dose.
Drug interactions with VANRAFIA
OATP1B1/1B3 inhibitors:
Avoid concomitant use with organic anion transporting polypeptides 1B1/1B3 (OATP1B1/1B3) inhibitors. VANRAFIA is an OATP1B1/1B3 substrate. Concomitant use with an OATP1B1/1B3 inhibitor increases the exposure of VANRAFIA, which may increase the risk of adverse reactions.
Strong or moderate CYP3A inducers:
Avoid concomitant use with a strong or moderate CYP3A inducer. VANRAFIA is a CYP3A substrate. Concomitant use with a strong or moderate CYP3A inducer is expected to decrease the exposure of VANRAFIA, which may reduce the efficacy of VANRAFIA.
Start your patients on VANRAFIA
Help your eligible patients start and stay on VANRAFIA